Â鶹Æƽâ°æ

Posters presentation with Novadiscovery and Calvagone at the PAGE Meeting

Published on 31/05/2018

Â鶹Æƽâ°æ is pleased to collaborate with Novadiscovery and Calvagone which will present the first in silico liver disease model and the pharmackinetics-pharmacodynamics analysis respectivelly of EYP001 treatment effect on Hepatitis B virus (HBV) infected patients at the PAGE Meeting, May 29th – June 1st, 2018 in Switzerland.

Read next in 'Latest news'

• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH